Research progress in antibody drug therapy for relapsed/refractory diffuse large B-cell lymphoma
- VernacularTitle:抗体药物治疗复发/难治性弥漫性大B细胞淋巴瘤的研究进展
- Author:
Yanyan SUN
1
;
Weichen ZHAO
1
;
Chunyuan HE
1
;
Yimiao XIA
1
;
Wei ZHOU
1
;
Yuanyuan ZHEN
1
;
Junjie JIANG
1
;
Facai WANG
1
Author Information
- Publication Type:Journal Article
- Keywords: relapsed/refractory diffuse large B-cell lymphoma; monoclonal antibodies; bispecific antibodies; antibody-drug conjugate
- From: China Pharmacy 2025;36(13):1677-1682
- CountryChina
- Language:Chinese
- Abstract: Diffuse large B-cell lymphoma(DLBCL)is a highly heterogeneous disease.Although standard first-line regimens can cure＞50%of patients,approximately one-third of them develop relapsed/refractory DLBCL(r/r DLBCL).Consequently,immunotherapy targeting molecular abnormalities has become pivotal for managing r/r DLBCL.The results of this review show that with advances in understanding DLBCL pathogenesis and the tumor immune microenvironment,antibody-based therapies have evolved rapidly,progressing from monoclonal antibodies(e.g.,rituximab,tafasitamab)to bispecific antibodies(e.g.,odronextamab,glofitamab,epcoritamab)and antibody-drug conjugate(e.g.,polatuzumab vedotin,loncastuximab tesirine).These engineered agents enhance immune cytotoxicity and tumor-specific targeting,providing novel therapeutic options for r/r DLBCL patients.
